Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage...

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity – Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need ...